BREATHER Plus

What is this study about?

The goal of HIV treatment is to make sure the amount of HIV virus in the blood remains very low. This is called having an undetectable viral load. If this goal is achieved and sustained life-long, then people living with HIV can live a healthy life, with a normal life expectancy. However, it is challenging to take medication every single day for life. This may be an even bigger challenge for teenagers living with HIV.

In BREATHER Plus we will compare two different ways of taking HIV medicines that include the HIV medicine dolutegravir. We want to see if a similar proportion of young people in the Short Cycle Therapy group have low HIV virus as in the Continuous Treatment group and whether they find there are other benefits to having two days off treatment each week:

• Short Cycle Therapy: where people taking part will take all their HIV medicines during the week but stop taking them at weekends (either Friday and Saturday or Saturday and Sunday)
• Continuous Treatment: where people taking part will take all their HIV medicines every day without any interruptions

 People joining BREATHER Plus will have an equal chance of being randomised to one of the two groups.

Type of study

Randomised trial

Contact details

mrcctu.bplata@ucl.ac.uk

Who is funding the study?

This project is part of the EDCTP2 Programme supported by the European Union.

The European and Developing Countries Clinical Trials Partnership (EDCTP2) is a collaboration between countries in Europe and sub-Saharan Africa supported by the European Union, to improve the health of Africans by doing important research trials.